Par Responds To Process Patents: FineTech Acquisition Valued At $109 Mil.
Executive Summary
Par's acquisition of ISP's FineTech chemical business reflects the generic drug company's desire to gain greater control over all aspects of the manufacturing process in the current environment of patent disputes